Updated Miv-cel Data at EULAR Shows Substantial Reduction in Refractory RA
KYTX has more than doubled off its 52-week low of $2.52.
Summary
Kyverna Therapeutics presented updated Phase 1 data for its lead candidate, miv-cel, at the EULAR 2026 Congress, demonstrating a substantial reduction in disease activity in ACPA-positive, treatment-refractory rheumatoid arthritis patients. The data showed a majority of patients achieved ACR70 response by Week 36 and evidence of an immune reset. This positive update reinforces miv-cel's broad potential across autoimmune diseases, following recent strong data in myasthenia gravis and a BLA submission for Stiff Person Syndrome. The results further validate the drug's mechanism and expand its potential market opportunity in a difficult-to-treat patient population. The Phase 2 portion of the COMPARE trial, comparing miv-cel to rituximab, is fully enrolled.
At the time of this announcement, KYTX was trading at $8.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $480.3M. The 52-week trading range was $2.52 to $13.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.